Polaris Partners, a venture capital firm, led a $126m Series A funding round in Tessa Therapeutics, a developer of a biotechnology platform, with participation from Temasek, EDBI, Heliconia Capital and Heritas Capital. “We are very pleased to have secured this significant round of financing from such a highly regarded syndicate of global healthcare investors, including Temasek and Polaris Partners. Additionally, we are excited to welcome Amy Schulman and Darren Carroll of Polaris to our Board of Directors and look forward to benefitting from their substantial industry experience and business acumen as Tessa enters an important period of growth as we advance our pipeline of revolutionary cell therapies through the clinic to patients in need," Göran Ando, Tessa Therapeutics Chairman of the Board.